“…48,49 The only FDA-approved drug is tPA with limited treatment window and high risk of hemorrhagic transformation; hence, there is a significant need for finding a novel treatment for stroke. Recently, stem cell therapy has emerged as a promising experimental treatment, even reaching clinical trials, for neurological diseases, including stroke, 49,50 possibly due to the grafted cells' bystander effects such as secretion of growth factors and cytokines associated with neurogenesis, angiogenesis, vasculogenesis, and mitochondrial repair. 48,49,51,52 Here, we demonstrated the appealing therapeutic properties of NCS-01 cells, namely cell secretion of bFGF and IL-6, and filopodia extension in rescuing ischemic cells.…”